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Decreased Activity of the Na/H Exchanger by
Phosphodiesterase 5A Inhibition Is Attributed to an Increase
in Protein Phosphatase Activity
Alejandra M. Yeves, Carolina D. Garciarena, Mariela B. Nolly, Gladys E. Chiappe de Cingolani,
Horacio E. Cingolani, Irene L. Ennis
Abstract—The beneficial effect of phosphodiesterase 5A inhibition in ischemia/reperfusion injury and cardiac hypertrophy
is well established. Inhibition of the cardiac Na/H exchanger (NHE-1) exerts beneficial effects on these same
conditions, and a possible link between these therapeutic strategies was suggested. Experiments were performed in
isolated cat cardiomyocytes to gain insight into the intracellular pathway involved in the reduction of NHE-1 activity
by phosphodiesterase 5A inhibition. NHE-1 activity was assessed by the rate of intracellular pH recovery from a
sustained acidic load in the absence of bicarbonate. Phosphodiesterase 5A inhibition with sildenafil (1 mol/L) did not
affect basal intracellular pH; yet, it did decrease proton efflux (JH; in millimoles per liter per minute) after the acidic
load (proton efflux: 6.970.43 in control versus 3.310.58 with sildenafil; P0.05). The blockade of both protein
phosphatase 1 and 2A with 100 nmol/L of okadaic acid reverted the sildenafil effect (proton efflux: 6.770.82). In
contrast, selective inhibition of protein phosphatase 2A (1 nmol/L of okadaic acid or 100 mol/L of endothall) did not
(3.861.0 and 2.611.2), suggesting that only protein phosphatase 1 was involved in sildenafil-induced NHE-1
inhibition. Moreover, sildenafil prevented the acidosis-induced increase in NHE-1 phosphorylation without affecting
activation of the extracellular signal–regulated kinase 1/2-p90RSK pathway. Our results suggest that phosphodiesterase
5A inhibition decreases NHE-1 activity, during intracellular pH recovery after an acidic load, by a protein phosphatase
1–dependent reduction in NHE-1 phosphorylation. (Hypertension. 2010;56:690-695.)
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The cardiac Na/H exchanger (NHE-1) is a 110-kDaglycoprotein expressed at high levels in the myocardium. It
extrudes protons concomitantly with Na influx in a 1:1 stoi-
chiometric relationship, rendering the process electroneutral. It
has 2 major domains, an NH2-terminal membrane transport
domain followed by a carboxyl-terminal cytosolic regulatory
domain. NHE-1 plays a critical role in a number of cardiovas-
cular disorders including ischemia/reperfusion injury, cardiac
remodeling after myocardial infarction, and the development of
pathological cardiac hypertrophy.1–3 Moreover, its specific inhi-
bition has beneficial effects in these circumstances.4–9 In the last
few years, inhibition of the cGMP-catabolizing enzyme, phos-
phodiesterase 5A (PDE5A), by sildenafil (SIL) has been repeat-
edly reported to have a beneficial effect in similar pathological
conditions.10–15 By inhibiting PDE5A, SIL raises cytosolic
cGMP concentrations leading to protein kinase G (PKG) acti-
vation. This kinase has been shown, using pharmacological and
gene knockdown approaches, necessary for the cardioprotective
action of SIL.13 However, the downstream targets/mechanism
involved in this protective effect remain to be elucidated.
Interestingly, we recently demonstrated that the beneficial effect
exerted by PDE5A inhibition, on postmyocardial infarction
remodeling in rats, was accompanied by a PKG-dependent
inhibition of NHE-1 activity.16 It was also reported that, in renal
mesangial cells, an increase in PKG activity induced NHE-1
inhibition during recovery from an acidic load.17
The present study was designed to gain further insight into
the cellular mechanism involved in the induction of NHE-1
inhibition by PDE5A inhibition. Therefore, we explored the
effect of SIL during intracellular pH (pHi) recovery after
sustained (5 minutes) intracellular acidosis. Evidence will be
presented supporting the hypothesis that cGMP accumulation
(because of PDE5A inhibition by SIL) promotes protein
phosphatase 1 (PP1) activation, which, in turn, dephosphor-
ylates the regulatory cytosolic tail of the NHE-1, decreasing
the exchanger activity.
Methods
All of the procedures followed during this investigation conform to
the Guide for the Care and Use of Laboratory Animals published by
the National Institutes of Health (NIH Publication No. 85-23, revised
1996), and the experimental protocol was approved by the La Plata
School of Medicine Animal Welfare Committee. Cats (body weight:
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3 to 4 kg) were anesthetized by IP injection of sodium pentobarbital
(35 mg/kg of body weight), and hearts were rapidly excised when
plane 3 of phase III of anesthesia was reached.
For a detail description of the methods, please see the online Data
Supplement at http://hyper.ahajournals.org.
Results
NHE-1 activity was assessed by the rate of pHi recovery from
a sustained acidic load in the absence of bicarbonate. Because
NHE-1 activity is regulated by intracellular H concentra-
tion, proton efflux (JH) comparison among different groups
was done at a common pHi of 6.8. PDE5A inhibition with SIL
did not affect basal pHi (Figure 1A); yet, it did significantly
decrease the rate of pHi recovery after a sustained acidic load
(Figure 1B).
It is well known that NHE-1 activity correlates well with
its level of phosphorylation. Considering that sustained intra-
cellular acidosis activates the extracellular signal–regulated
kinase (ERK) 1/2-p90RSK cascade, leading to phosphoryla-
tion of the cytosolic tail of the exchanger,18 we explored the
phosphorylation state of these kinases after acidosis not only
in control conditions but also in the presence of SIL.
Sustained intracellular acidosis significantly increased
ERK1/2 and p90RSK phosphorylation, and PDE5A inhibition
with was not able to prevent this increase. No effect of SIL on
ERK1/2-p90RSK basal phosphorylation was evidenced (Fig-
ure 2) The fact that SIL suppressed acidosis-induced NHE-1
activity without inhibiting the kinase pathway that underlies
the enhanced function of the exchanger suggested to us that a
different mechanism was involved in this effect. To get
further insight into it, we decided to explore NHE-1 phos-
phorylation by a phosphospecific antibody, which recognizes
the phospho-Ser703 in the 14-3-3 protein binding motif of the
carboxyl tail of the NHE-1. This site has been shown to be the
target for p90RSK.19,20 As expected, the acidosis-induced
activation of the ERK1/2-p90RSK pathway increased NHE-1
phosphorylation at Ser703. Interestingly, PDE5A inhibition
completely blunted this effect on the exchanger’s cytosolic
regulatory domain; however, SIL has no effect on Ser703-
NHE-1 phosphorylation under control conditions (Figure 3).
Because we found that ERK1/2 and p90RSK phosphorylation
was not altered by SIL, we speculated that the effect of
PDE5A inhibition on NHE-1 phosphorylation might be be-
cause of activation of phosphatases. To explore this hypoth-
esis, we analyzed the SIL effect on NHE-1 activity (JH) in the
presence of the phosphatase inhibitor, okadaic acid. As
shown in Figure 4, 100 nmol/L of okadaic acid, a concentra-
tion that inhibits both PP1 and PP2A activity, completely
prevented the inhibitory effect of SIL on NHE-1. However,
when the concentration of okadaic acid was lowered to 1
nmol/L to make it selective for PP2A,21,22 no attenuation of
the SIL effect was observed. A similar result was found when
endothall, another phosphatase inhibitor that has been re-
ported to exhibit greater selectivity for PP2A,23 was assayed.
These results suggested that PP1, but not PP2A, was directly
involved in the inhibitory effect on NHE-1 by PDE5A
inhibition.
To elucidate whether PP1 directly dephosphorylates the
cytosolic tail of the NHE-1, we determined the phosphoryla-
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Figure 2. Acidosis-induced ERK1/2-p90RSK activation: effect of
PDE5A inhibition. ERK1/2 and p90RSK activation was deter-
mined by immunoblot with antibodies specific to the phosphory-
lated form of each kinase. Acidosis induced a significant
increase in both, an effect that was not prevented when acidosis
occurred in the presence of SIL. No differences in total ERK-2
and p90RSK were observed between groups. The “n” for each
experimental group is indicated between brackets. *P0.05 vs
all other groups, ANOVA.
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Figure 1. A, NHE-1 activity under PDE5A inhibition.
Steady-state pHi values were determined in
bicarbonate-free medium to solely evaluate NHE-1
activity. The basal pHi was not significantly modified by
PDE5A inhibition with SIL (1 mol/L). B, When NHE-1
activity was measured during recovery from a sus-
tained acidic load, it was significantly reduced by
PDE5A inhibition with SIL. Insert, Schematic represen-
tation of the pHi recordings during the experimental
protocol followed. Transient exposure to NH4Cl was
used to induce, by its washout, intracellular acidosis.
The duration of intracellular acidosis was extended by
an initial washout with Na-free solution, and NHE-1
was reactivated by reintroduction of extracellular Na.
JH comparison among different groups was done at a
common pHi of 6.8. The “n” for each experimental
group is indicated between brackets. *P0.05, Student
t test.
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tion state of the exchanger at Ser703 in the presence of SIL in
combination with the protein phosphatase inhibitor okadaic
acid. When the highest concentration of okadaic acid (100
nmol/L; both PP1 and PP2A are inhibited) was assayed in
combination with SIL, no reduction in acidosis-induced
NHE-1 phosphorylation was observed. However, when oka-
daic acid was assayed at a lower concentration (1 nmol/L;
only PP2A is inhibited) SIL effect was not prevented,
confirming the involvement of PP1 in the inhibitory action of
SIL on NHE-1 activity. Protein phosphatase inhibition with
100 nmol/L of okadaic acid did not significantly alter
acidosis-induced Ser703-NHE-1 phosphorylation (Figure 5).
Discussion
The original finding of the present study is that PDE5A
inhibition decreases NHE-1 phosphorylation through the
activation of a protein phosphatase (PP1) without interfering
with the ERK-p90RSK pathway. A schematic representation is
shown in Figure 6.
The NHE-1 activity is regulated primarily by intracellular
H concentration. It is low at steady-state physiological
conditions but increases markedly in response to intracellular
acidosis through the interaction of H with an allosteric
modifier site within the transport domain.24 However, addi-
tional regulation of NHE-1 activity occurs in response to
stretch, altered cell volume, and several neurohumoral factors
by posttranslational modification of the carboxyl-terminal
cytosolic regulatory tail that modifies the affinity of the
allosteric site for H.25–27 Not only the extent but also the
duration of intracellular acidosis regulates NHE-1 activity.
Extending the duration of intracellular acidosis has a stimu-
latory effect on NHE-1 activity that depends on the activation
of the ERK pathway.18,28,29 This kinase cascade has been
shown to phosphorylate the regulatory domain of the ex-
changer, increasing its activity.29–32 In this context, the
present study provides insight into a novel regulatory mech-
anism of NHE-1 activity. We showed that PDE5A inhibition
completely blunted the acidosis-induced increase in Ser703
NHE-1 phosphorylation and significantly reduced JH after a
sustained acidic load (by 50%). The rationale for studying
NHE-1 activity after sustained instead of acute intracellular
acidosis was that the former better resembles physiopatho-
logic conditions.
Because the level of phosphorylation of a protein depends
on the balance between kinase and phosphatase activity, and
SIL significantly decreased NHE-1 phosphorylation at
Ser703 without interfering with ERK/p90RSK activation, we
speculated that PKG activation promoted an increase in
phosphatase activity responsible for NHE-1 dephosphoryla-
tion. This hypothesis was confirmed by determining JH and
NHE-1 phosphorylation in the presence of SIL plus phospha-
tase inhibitors. We found the effect of SIL on the NHE-1 was
completely reverted by inhibiting PP1, whereas PP2A ap-
peared not to be involved under our experimental conditions
and in agreement with a previous report.33 We did not detect
any effect of PDE5A inhibition on ERK-p90RSK phosphory-
lation, contrary to the finding of Kukreja and colleagues.13,34
The reason for this difference is not apparent to us at present.
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Figure 3. Acidosis-induced NHE-1 phosphorylation: effect of
PDE5A inhibition. The acidosis-induced increase in ERK1/2-
p90RSK phosphorylation was accompanied by an increase in
NHE-1 phosphorylation at Ser703, estimated by a specific anti-
body against the P-14-3-3 binding motif (BM). This effect was
prevented by PDE5A inhibition (SIL, 1 mol/L). SIL did not affect
Ser703-NHE-1 phosphorylation under control conditions (in the
absence of sustained acidosis). The “n” for each experimental
group is indicated between brackets. *P0.05 vs all other
groups, ANOVA.
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Figure 4. SIL effect on NHE-1 activity under protein phospha-
tase inhibition. The inhibitory effect of SIL on NHE-1 activity (JH)
was explored in the presence of the phosphatase inhibitor oka-
daic acid during the recovery from sustained acidic loads.
NHE-1 activity was significantly increased when PP1 activity
was inhibited by 100 nmol/L of okadaic acid (OAc 100). On the
contrary, selective inhibition of PP2A (1 nmol/L of okadaic acid
[OAc 1]; or 100 mol/L of endothall) did not prevent SIL effect
on NHE-1 activity. The “n” for each experimental group is indi-
cated between brackets. *P0.05 vs all other groups, ANOVA.
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Intracellular Na accumulation is a key determinant of
cardiovascular injury in several pathological conditions, such
as ischemic/reperfusion injury and heart failure, and50% of
Na entry to the myocytes is through the NHE-1.35 There-
fore, SIL-induced NHE-1 inhibition may explain, at least
partially, the cardioprotective effect of this compound. Some
other cellular targets and mechanism for PDE5A-inhibition
consequences have been anticipated recently. In a mouse
model of cardiac pressure overload, PKG-dependent phos-
phorylation of the regulator of G protein signaling 2 was
proposed to mediate the beneficial effect of SIL.15 Moreover,
investigators from this same group have reported lately
another novel mechanism underlying the suppression of
pathological cardiac hypertrophy by PDE5A inhibitors.36
They showed that transient receptor potential canonical chan-
nels were negatively modulated by PKG-dependent phos-
phorylation.36 These stretch sensitive nonselective cationic
channels can be responsible for increases in Na and/or Ca2
influx mimicking NHE-1 activation. Whether SIL-favored
PKG phosphorylation of a transient receptor potential canon-
ical channel is involved in our results was not explored by us
but deserves to be considered.
We think the findings of the present work are potentially
relevant for the in vivo treatment of several cardiovascular
pathologies. Recently, an interesting article by Pokreisz et
al37 reported that PDE5A expression was markedly greater in
the left ventricle of patients with dilated and ischemic
cardiomyopathy than in unused donor left ventricular tissues.
These same investigators found in transgenic mice with
PDE5A cardiomyocyte–specific overexpression that this does
not affect baseline cardiac function but predisposes mice to
adverse left ventricular remodeling after myocardial infarc-
tion. This is in line with our previous results in which PDE5A
inhibition after coronary artery ligation significantly amelio-
rated postmyocardial remodeling and left ventricular dys-
function in rats.16 It is important to note that NHE-1 inhibition
through SIL seems not to influence cardiac function and
growth under basal conditions, probably limiting by this way
potential undesired effects. Based on our previous and present
findings, as well as those from others,13,15,37,38 PDE5A
inhibition seems to emerge as an important therapeutic target.
A possible limitation of our study is the reliance on
pharmacological inhibitors to analyze the mechanisms in-
volved in PDE5A inhibition-induced consequences. Although
at the concentrations used herein these pharmacological
compounds have been widely used and probed to be valid
tools, the possibility of undesired nonspecific effects of some
of them cannot be completely ruled out. On the other hand,
we have preliminary results of similar experiments performed
in rat papillary muscles in which SIL induces NHE-1 dephos-
phorylation and inhibition consistently with the results of this
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Figure 5. NHE-1 phosphorylation under protein phosphatase
inhibition. PDE5A inhibition with SIL decreased acidosis-induced
NHE-1 phosphorylation at Ser703, estimated by a specific anti-
body against P-14-3-3 binding motif (BM). This effect was pre-
vented when both PP1 and PP2A were inhibited (100 nmol/L
of okadaic acid). However, when only PP2A was inhibited (1
nmol/L of okadaic acid), SIL effect on NHE-1 phosphorylation
was not prevented, suggesting that only PP1 was the culprit for
NHE-1 dephosphorylation under these experimental conditions.
The dash line indicates the value of NHE-1 Ser703 phosphoryla-
tion induced by acidosis in the absence of SIL. *P0.05 vs all
other groups; ANOVA A: representative blots, top: P-14-3-3
binding motif signal in immunoprecipitated NHE-1 samples; bot-
tom: NHE-1 signal of the same samples, as loading control. C,
Sustained acidosis in the presence of 100 nmol/L of okadaic
acid (AcOka 100) induced a significant increase in NHE-1
phosphorylation at Ser703 compared with control (C) that was
of a similar magnitude to that induced by acidosis itself.
*P0.05 vs control, t test. The “n” for each experimental group
is indicated between brackets.
Sustained 
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RSKp90
cGMP5’GMP PP1
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Figure 6. Schematic representation of the hypothesis tested
and results obtained. Sustained intracellular acidosis has a stim-
ulatory effect on NHE-1 activity that depends on the activation
of the ERK1/2-p90RSK pathway that phosphorylates the regula-
tory domain of the exchanger.18,28–32 PDE5A promotes cGMP
accumulation and PKG activation, which, in turn, and by a yet-
unknown mechanism, favors PP1 activity, which will dephos-
phorylate the regulatory cytosolic tail of the NHE-1, decreasing
its activity.
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article; however, in that case, PP2A seems to be involved.
Whether species differences could be the culprit for this
discrepancy is not apparent to us at present.
Perspectives
NHE-1 inhibition is a powerful therapeutic tool in many
cardiovascular pathologies, namely ischemia/reperfusion in-
jury and cardiac hypertrophy/remodeling. Recently, the inhi-
bition of PDE5A has emerged as a promising novel strategy
for almost these same cardiac disorders.13,14,38 SIL is the most
widely experimentally and clinically used PDE5A inhibitor.
It was the first oral medicine approved for treating erectile
dysfunction, and it has another clinically approved use for
treatment of pulmonary arterial hypertension. In a recent
study we reported a possible link between both therapeutic
strategies: chronic treatment with SIL improved postmyocar-
dial infarction remodeling and function through PKG-
dependent inhibition of the NHE-1.16 However, other cellular
targets have been also proposed to underlie the cardioprotec-
tive effect of SIL.15,36 In the present study we provide insight
into the intracellular pathway involved in the NHE-1–inhib-
itory effect of SIL, supporting a critical role of PP1 in NHE-1
dephosphorylation and inhibition. Additional research will be
necessary to completely elucidate the intracellular mecha-
nisms involved in PDE5A inhibition cardiovascular benefi-
cial effects and their relative importance. On the other hand,
pharmacological regulation of protein phosphatase activity
emerges as an option in the treatment of cardiac diseases.
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